0001193125-19-033119.txt : 20190211 0001193125-19-033119.hdr.sgml : 20190211 20190211083332 ACCESSION NUMBER: 0001193125-19-033119 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190211 DATE AS OF CHANGE: 20190211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Unum Therapeutics Inc. CENTRAL INDEX KEY: 0001622229 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465308248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90431 FILM NUMBER: 19582046 BUSINESS ADDRESS: STREET 1: 200 CAMBRIDGE PARK DRIVE STREET 2: SUITE 3100 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-945-5576 MAIL ADDRESS: STREET 1: 200 CAMBRIDGE PARK DRIVE STREET 2: SUITE 3100 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Unum Therapeutics, Inc. DATE OF NAME CHANGE: 20141014 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133529324 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 SC 13G 1 d689549dsc13g.htm SC 13G SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Unum Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

903214104

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 903214104

 

  1.    

Names of Reporting Persons

 

SANOFI

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☐        (b)  ☐

 

  3.  

SEC Use Only

 

  4.  

Citizenship or Place of Organization

 

The Republic of France

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

       5.     

Sole Voting Power

 

1,773,481 shares

      6.     

Shared Voting Power

 

0 share

      7.     

Sole Dispositive Power

 

1,773,481 shares

      8.     

Shared Dispositive Power

 

0 share

    9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,773,481 shares

  10.    

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

 

  11.  

Percent of Class Represented by Amount in Row (9)

 

5.91%

  12.  

Type of Reporting Person (See Instructions)

 

CO

 

 

2

Item 1.

 

  (a)

Name of Issuer

Unum Therapeutics, Inc.

 

  (b)

Address of Issuer’s Principal Executive Offices

200 Cambridge Park Drive, Suite 3100

Cambridge, Massachusetts 02140

 

Item 2.

 

  (a)

Name of Person Filing

Sanofi

 

  (b)

Address of Principal Business Office or, if none, Residence

54 Rue La Boétie, 75008 Paris (France)

 

  (c)

Citizenship

The Republic of France

 

  (d)

Title of Class of Securities

Common Stock, $0.001 par value

 

  (e)

CUSIP Number

903214104

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

3

(i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
(k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                     

 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned:

1,773,481 shares

 

  (b)

Percent of class:

5.91%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote

1,773,481 shares

 

  (ii)

Shared power to vote or to direct the vote

0 share

 

  (iii)

Sole power to dispose or to direct the disposition of

1,773,481 shares

 

  (iv)

Shared power to dispose or to direct the disposition of

0 share

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

Not applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

 

Aventisub LLC.*    1,773,481    5.91%

 

*

Shares are held of record by Aventisub LLC, a wholly-owned subsidiary of the Reporting Person.

 

4

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

Item 10.

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

5

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 11, 2019

Date

/s/ Alexandra Roger*

Signature

Alexandra Roger

Head of Securities Law and Capital Markets

Name/Title

 

*

Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.

 

6